Twist1, a basic helix-loop-helix transcription factor, plays a key role during development and is a master regulator of the epithelial-mesenchymal transition (EMT) that promotes cancer metastasis. Structure-function relationships of Twist1 to cancer-related phenotypes are underappreciated, so we studied the requirement of the conserved Twist box domain for metastatic phenotypes in prostate cancer (PCa). Evidence suggests that Twist1 is overexpressed in clinical specimens and correlated with aggressive/metastatic disease. Therefore, we examined a transactivation mutant, Twist1-F191G, in PCa cells using in vitro assays which mimic various stages of metastasis. Twist1 overexpression led to elevated cytoskeletal stiffness and cell traction forces at the migratory edge of cells based on biophysical single-cell measurements. Twist1 conferred additional cellular properties associated with cancer cell metastasis including increased migration, invasion, anoikis resistance, and anchorage-independent growth. The Twist box mutant was defective for these Twist1 phenotypes in vitro. Importantly, we observed a high frequency of Twist1-induced metastatic lung tumors and extra-thoracic metastases in vivo using the experimental lung metastasis assay. The Twist box was required for PCa cells to colonize metastatic lung lesions and extra-thoracic metastases. Comparative genomic profiling revealed transcriptional programs directed by the Twist box that were associated with cancer progression, such as Hoxa9. Mechanistically, Twist1 bound to the Hoxa9 promoter and positively regulated Hoxa9 expression in PCa cells. Finally, Hoxa9 was important for Twist1-induced cellular phenotypes associated with metastasis. These data suggest that the Twist box domain is required for Twist1 transcriptional programs and PCa metastasis.
1

The Twist Box Domain is Required for Twist1-induced Prostate Cancer Metastasis
Rajendra P. Gajula , Steven S. An 3, 5, 6 and Phuoc T. Tran 1, 6, 7, 9 ,*
INTRODUCTION
Prostate cancer is the most common cancer diagnosed in men in the United States and is responsible for the second most cancer deaths in men (1) . Patterns of disease failure in prostate cancer suggest understanding the determinants that confer progression of localized presentations to metastatic disease will result in the largest therapeutic gains (2) .
One mechanism by which cancer cells may acquire the characteristics necessary for metastasis is the epithelial-mesenchymal transition (EMT). EMT is a transcriptional program, crucial in early embryonic development that is co-opted by some cancer cells to facilitate aggressive and metastatic behavior (3) . Twist1 is a basic helix-loop-helix (bHLH) multi-domain transcription factor which directly mediates EMT by transcriptional activation and repression of E-box regulated target genes (4, 5) . A role for TWIST in prostate cancer pathogenesis has been suggested (6, 7) , but the role of EMT and Twist1 in prostate cancer disease progression and metastasis is just now being explored (8, 9) . The critical domains of Twist1 and the crucial Twist1 downstream transcriptional targets required for increased tumorigenicity and aggressive metastatic phenotypes in prostate cancer are unknown. The carboxyl-terminal Twist box is a highly conserved domain among Twist1 orthologues for which little functional information in the context of cancer phenotypes is known (5) . A greater understanding of the structure-function relationships and downstream targets of Twist1 may allow for an increased appreciation of the mechanisms responsible for Twist1-induced metastasis and may facilitate more precise inhibitory strategies of Twist1 as a therapeutic maneuver in cancer.
Here we used a single amino acid substitution mutation, Twist1 codon 191 phenylalanine-to-glycine (F191G), to study the role of the Twist box for Twist1-induced Twist box is needed for prostate cancer metastasis 8
Luciferase Promoter Reporter Assay
Sub-confluent cells were transfected using Lipofectamine 2000 (Invitrogen) with 200 ng of firefly luciferase reporter gene construct (100 ng was used for SNAI2 reporter assays), 100 ng of the pRL-SV40 Renilla luciferase construct and 500 ng of the Twist1 or Twist1-F191G mutant expression construct. Cell extracts were prepared 36h after transfection in passive lysis buffer and the reporter activity was measured using the Dual-Luciferase Reporter Assay System (Promega).
Wound-Healing Migration Assay
Two-dimensional migration assay was performed using a scratch/wound model. Cells were grown in 6 well plates for 24 hr to confluence. PC3 cells were treated with 500 pM TGF-beta at the time of wounding. Multiple scratch wounds were created using a P-20 micropipette tip and cells fed with fresh complete media. Five representative fields of the wound were marked and images were taken at 0 and 24-h after wounding. Relative wound closure is calculated from the remaining wound area normalized to the initial wound area using ImageJ software (NIH Image, Bethesda, USA).
Biophysical Assays
Fourier transform traction microscopy (FTTM) was used to measure the contractile stress arising at the interface between each adherent cell and its substrate as described (47) . Briefly, cells were plated sparsely on elastic collagen type I coated gel blocks. Twist box is needed for prostate cancer metastasis 9 taken at different times with cell-free reference (traction-free) images. The displacement field between a pair of images was then obtained by identifying the coordinates of the peak of the cross-correlation function (31, 32) . From the displacement field and known elastic properties of the gel (Young's modulus of 1 kPa with a Poisson's ratio of 0.48), the cell traction field was computed. The computed traction field was used to obtain net contractile moment, which is a scalar measure of the cell's contractile strength, expressed in pico-Newton meters (pNm).
Magnetic twisting cytometry (MTC) was used to measure material properties of the cytoskeleton as described (28, 29) . In brief, cells were plated at 150,000 cells/cm 
Matrigel Invasion Assay
The invasion potential was assessed using Chemicon cell invasion assay kit (Millipore, USA) as direct by the manufacturer. 8 µM transwells with Matrigel were used for the assay. Serum starved 0.5-1X 10 6 cells (12-16 hr) in 300 µl were seeded in upper chambers while lower wells were filled with 500 µl of 10% FBS complete medium. Invading cells on the lower surface were fixed and stained. The stain is dissolved in 200 µl of 10% acetic acid and measured at 570 nm.
Invasive potential is derived by normalizing with the readings from blank transwell inserts.
Immunohistochemistry (IHC), Immunofluorescence (IF) and Western Blotting
IHC, IF and Western blotting was performed as described previously (48). 
Anoikis Assay and Apoptosis Assessment
Anoikis resistance was measured using a modified protocol (49). Cells were grown in normal attachment and ultra-low attachment (Corning, NY) 6 well plates. 24-hr later cells were blocked in 5% FBS and stained with Alexa Fluor 488 conjugated AnnexinV followed by propidium iodide (PI) staining (50µg/ml) (Invitrogen). Cells were enumerated on a BD FACS Caliber (BD Biosciences, San Jose, CA) and analysis was done using FloJo analysis software. All conditions were n=4 and two replicates per experiment.
Clonogenic Survival and Soft Agar Colony Formation Assays
Clonogenic survival was performed as previously described (50). Soft agar clonogenic assays used six well plates pre-coated with 1ml of basal 0.6% agarose in complete media and overlaid with 2 ml of cells (5 X 10 3 cells/ml) mixed with 0.3% agarose in complete media and allowed to solidify. The wells were constantly fed with complete media to prevent drying of agarose and then after 10-15 days of incubation colonies were scored under phase contrast microscopy. All conditions were repeated at least twice with 3 wells per experiment.
Animal Models and Histology
All procedures were carried out in accordance with the Johns Hopkins Animal Care and Use Committee, maintained under pathogen-free conditions and given food and water ad libitum. 
Microarray Data Acquisition and Analysis
Microarrays were performed using GeneChip WT cDNA Synthesis and amplification Kit and (Figure 1a , p=0.002 for aggregate). Further analysis of one of these microarray studies (11) showed that TWIST1 overexpression correlated with metastatic disease (Figure 1b Twist box is needed for prostate cancer metastasis 16 Twist1 overexpression increases cellular motility that is partially defective in the Twist1-
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F191G mutant
We next examined Twist1-induced cell migration and correlates of cell mechanics using the scratch/wound healing model. For this study, we made a scratch into an ensemble of confluent Myc-CaP cells (Figure 3a) and measured the spatiotemporal changes in forced motions of microbeads anchored to the cytoskeleton (CSK) through integrin cell adhesion receptors (28, 29) .
Using magnetic twisting cytometry (MTC), we measured cytoskeletal stiffness (g') and internal friction (g") before, immediately after and 24-hour after making a scratch. Over five decades of frequency, we found no differences in stiffness g' and friction g" between isogenic Myc-CaP cell Twist box is needed for prostate cancer metastasis 18 cells (Figure 4b, p=0.156 ). Similar to motility, the Twist box is at least partially required for Twist1-induced prostate cancer invasion.
The resistance to anoikis facilitates metastasis of cancer cells to distant organs. Both Twist1 overexpressing Myc-CaP and PC3 cells showed decreased apoptosis when grown in suspension compared to their isogenic Vector control cells (Figure 4c-f, both cell lines p<0.05) .
The Twist1-F191G mutant in Myc-CaP and PC3 cells were similar to their isogenic Vector control cells (Figure 4c-f, both cells p>0.47) for anoikis resistance. We also observed that the Twist box was required to confer radioresistance to prostate cancer cells (Supplementary Figure   S8) . Altogether, these data show that Twist1 overexpression can confer resistance to multiple cell death stimuli and that the Twist box domain is required for these Twist1 activities in prostate cancer cells. Gene set enrichment analysis (GSEA) (33) was used to identify gene sets which were overrepresented in Twist1 but not Twist1-F191G. Many of the overrepresented gene sets were related to phenotypes which we directly assayed, aggressive cellular behavior and metastasis, and were observed with overexpression of Twist1 but not Twist1-F191G (Figure 6c Twist box is needed for prostate cancer metastasis 22
DISCUSSION
Our study shows that Twist1 overexpression in prostate cancer cells induces an EMT phenotype, augments migration, invasion, resistance to anoikis and metastasis. We show that the highly conserved Twist box domain is required for many of these properties of Twist1 associated with aggressive tumor cell behavior in vitro and most importantly for metastasis in vivo. We also demonstrate that the Twist box domain is required for the full transcriptional activity of Twist1 and facilitates these pro-metastatic cellular functions by directing specific transcriptional programs. We show that Twist1 directly regulates the transcriptional pro-metastatic target In a recent study, the Twist box was required for Twist1 binding to the NF-kB subunit RELA to activate transcriptional activity, increased DNA binding affinity to the interleukin 8 (IL-8) promoter and transcriptional activation that was required for breast cancer cell invasion in vitro (38) . We did not observe direct Twist box-dependent regulation of IL-8 by Twist1 in our system, but in agreement with this study, we did observe Twist box-dependent gene sets consistent with NF-kB regulated inflammatory genes. The Twist box has also recently been shown to bind p53 and induce destabilization via MDM2-mediated degradation in sarcoma cells (39) . This mechanism is separate from Twist1 indirect regulation of p53 by modulating the ARF/MDM2/p53 pathway (40). We do not believe that Twist box-dependent p53 regulation explains the Twist1-induced metastatic phenotypes we observed in prostate cancer cells as PC3 cells are TP53-null and a similar Twist1-F191L substitution mutation in the Twist box did not affect Twist1-p53 interaction (39) . Our study findings require validation in other cancer histologies before our results can be generalized further and confirmation using autochthonous transgenic models of tumorigenesis and spontaneous metastasis models are needed. Despite TWIST1 expression levels appear to be correlated with prostate cancer aggressiveness and factors associated with lethal metastatic disease [ Figure 1 and (7, 24) ]. The down-regulation of Twist1 in androgen independent prostate cancer cells increased their sensitivity to anticancer drugs and suppressed their migration and invasion abilities, suggesting Twist1 inactivation as a potential therapeutic strategy (7) . TWIST1 expression during postnatal life is restricted tightly to a subpopulation of mesoderm derived tissues and limited studies suggest that Twist1 inhibition systemically may be well tolerated (41). Furthermore, our previous study suggested that suppression of Twist1 to physiological levels in vivo is sufficient for anti-cancer effects (42) .
However, the direct inhibition of Twist1 as a therapeutic maneuver still poses a few potential challenges. First, Twist1 is a pleiotropic transcription factor essential for mammalian development (43) . Secondly, bHLH transcription factors have been difficult to target directly with small molecules (44) 
